You are here: Home: HOU 3 | 2008 Audio: HOU 3 | 2008
 
 
  Go to interview with Bruce D Cheson, MD
Go to interview with Hagop M Kantarjian, MD
Go to interview with Sagar Lonial, MD


 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
Bruce D Cheson, MD
Head of Hematology
Director of Hematology Research
Georgetown University Hospital
Lombardi Comprehensive
Cancer Center
Washington, DC

 
  Click here to download the entire interview  
Track 1 Bendamustine in combination with rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin lymphoma (NHL)
Track 2 Mechanisms of action and synergy of bendamustine and rituximab
Track 3 Side effects and tolerability of bendamustine
Track 4 Potential roles for bendamustine in the treatment of NHL
Track 5 Ongoing trials of combination regimens with bendamustine in NHL
Track 6 Lenalidomide for the treatment of B-cell malignancies

Track 7 Tumor lysis syndrome/tumor flare reaction in lenalidomide-treated chronic lymphocytic leukemia (CLL)
Track 8 Rasburicase in the management of tumor lysis syndrome
Track 9 Clinical trials of lenalidomide in hematologic malignancies and solid tumors
Track 10 Perspective on the German DENSE-R-CHOP-14 trial in diffuse large B-cell lymphoma (DLBCL)
Track 11 International Harmonization Project consensus on imaging and response assessment in lymphoma
Track 12 Recommendations for the use of PET for response assessment in lymphoma
Track 13 Therapeutic algorithm for the initial management of follicular lymphoma
Track 14 Questions and controversies regarding maintenance rituximab in follicular lymphoma
Track 15 Challenges in the clinical use of radioimmunotherapy for NHL
Track 16 Role of rituximab in the treatment of mantle-cell lymphoma
     
Hagop M Kantarjian, MD
Chairman and Professor
Leukemia Department
The University of Texas
MD Anderson Cancer Center
Houston, Texas

 
  Click here to download the entire interview  
Track 1 Current issues with imatinib for the treatment of chronic myeloid leukemia (CML)
Track 2 Patient compliance with imatinib therapy
Track 3 Current major clinical research questions in CML
Track 4 Recommendations for molecular monitoring in CML
Track 5 Recent advances and current clinical questions in the treatment of CLL
Track 6 Therapeutic options for elderly patients with CLL
Track 7 Treatment approach for patients with fludarabine-refractory CLL

Track 8 Side effects of novel agents in the management of CLL: lenalidomide, bendamustine and alemtuzumab
Track 9 Role of lymphocyte count and disease burden in initiating therapy for CLL
Track 10 Prognosis of childhood and adult acute lymphocytic leukemia (ALL)
Track 11 Classification and treatment of adult ALL
Track 12 Development of novel treatments for ALL
Track 13 Role of allogeneic bone marrow transplantation in ALL
Track 14 The evolution of treatment for acute myeloid leukemia (AML)
Track 15 Novel treatments for acute promyelocytic leukemia
Track 16 Investigations of FMS-like tyrosine kinase 3 (FLT3) inhibitors in AML
Track 17 Evaluation of lower-intensity therapies for elderly patients with AML: clofarabine, azacitidine and decitabine
Track 18 Therapeutic options for myelodysplastic syndrome (MDS)
Track 19 Initial treatment for patients presenting with MDS
Track 20 Use of the DNA hypomethylating agent azacitidine for patients with higher-risk MDS
     
Sagar Lonial, MD
Associate Professor
Director of Translational Research
B-cell Malignancy Program
Department of Medical Oncology
and Hematology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia 		 
  Click here to download the entire interview  
Track 1 Optimizing the efficacy of induction therapy in multiple myeloma (MM)
Track 2 Evaluating biologically heterogeneous subsets of MM in an era of novel agents
Track 3 Key recent clinical trial reports in relapsed/refractory MM
Track 4 ECOG-E4A03: Lenalidomide with high-dose versus low-dose dexamethasone in newly diagnosed MM
Track 5 SWOG-S0232: High-dose dexamethasone with or without lenalidomide in newly diagnosed MM
Track 6 IFM 2005/01: Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated MM

Track 7 Bortezomib/thalidomide/dexamethasone (VTD) versus TD in preparation for ASCT in newly diagnosed MM
Track 8 Efficacy of lenalidomide/bortezomib/dexamethasone (RVD) in newly diagnosed MM
Track 9 Trials of RVD versus VD as up-front therapy for MM
Track 10 Clinical preference for the use of triplet — RVD or VTD — versus doublet therapy for newly diagnosed MM
Track 11 Algorithm for the use of post-transplant maintenance therapy
Track 12 Evaluation of novel drug combinations in MM

Track 13 Liposomal doxorubicin combined with bortezomib or lenalidomide for the treatment of relapsed/refractory MM
Track 14 Frequently asked questions in MM: Best induction regimen? Early versus late transplantation?
Track 15 Oral direct factor Xa inhibitor apixaban for the prevention of deep vein thrombosis
Track 16 Considerations in the development of novel targeted agents

Track 17 Importance of rapid reversal of renal insufficiency in patients with plasma cell disorders
Track 18 Algorithm for bisphosphonate therapy in MM